Taiki Kurino   Reiko Matsuda   Ayu Terui   Hiroyuki Suzuki   Tomomi Kokubo   Tomoya Uehara   Yasushi Arano   Akihiro Hisaka   Hiroto Hatakeyama   
Journal for ImmunoTherapy of Cancer 8(1) 2020年2月 [査読有り]
BACKGROUND: Recently, antiprogrammed cell death protein 1 (aPD-1) and antiprogrammed death-ligand 1 (aPD-L1) monoclonal antibodies (mAbs) have been approved. Even though aPD-1 and aPD-L1 mAbs target the same PD-1/PD-L1 axis, it is still unclear wh...